Chi­nese an­ti­body play­er chas­es Hong Kong IPO with lead Rit­ux­an chal­lenger ready for late-stage test

On­col­o­gy R&D has boomed in Chi­na with a sta­ble of home­grown biotechs churn­ing out late-stage clin­i­cal hope­fuls. Much of those have been so-called “me-too” drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.